New dual immunotherapy cuts death risk for extensive small-cell lung cancer

During the European Society of Medical Oncology meeting in Madrid, Jacob Sands from the Dana-Farber Cancer Institute disclosed results from a clinical trial evaluating a novel dual immunotherapy regimen for extensive-stage small-cell lung cancer. Patients received the two immunotherapy drugs immediately after completing chemotherapy, and the approach achieved a 58% reduction in the risk of death compared with standard treatment alone.

The presentation attracted considerable attention from the assembled oncology community. Benjamin Besse, deputy director of clinical research at the Institut Gustave-Roussy, emphasized how aggressive and rapidly progressing this cancer is once it has metastasized. He highlighted that while localized disease can sometimes be cured, options for the advanced stage have been limited. The new data suggest a promising therapeutic avenue that could improve survival outcomes for a patient group with historically poor prognoses.